MEDIA

The European Patent Office has granted Nanexa’s PharmaShell® patent

28 April, 2022
- Press Release
Download attachment

Nanexa AB (publ) today announced that the European Patent Office (EPO) has granted the company’s patent application relating to the drug delivery system PharmaShell®. The patent protection covers the manufacturing method of PharmaShell and products produced using the method.

“The route to a granted patent application may be long, and we have put a lot of effort into our discussions with EPO to achieve the strongest possible patent protection. It is with great satisfaction that I can now confirm that the PharmaShell patent is granted in Europe. We have all along been confident in our patent situation, but it is still meaning a lot to get it verified by EPO. With the patent granted we will be in an even more interesting position in discussions with potential partners.”, says David Westberg, CEO of Nanexa.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing parenteral drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

The European Patent Office has granted Nanexa’s PharmaShell® patent